Yasuhiro Suzuki 1 2, Mari Deguchi 1, Airi Furuya 1, Sayuki Kato 1, Shoichiro Ohta 3
Main idea: The effect of febuxostat treatment on cardiovascular events may be associated with protection against the infiltration of lymphocytes or monocytes through VCAM-1 induction in inflamed endothelial cells such as arterial sclerosis.
In a randomized trial, higher all-cause and cardiovascular mortality were observed in treatment with febuxostat than with allopurinol in patients with coexisting gout and serious cardiovascular conditions. Febuxostat or allopurinol can be used as an anti-inflammatory treatment to reduce the transcription of nuclear factor-kappa B and the production of relevant inflammatory factors. We evaluated the effect of febuxostat on vascular cell adhesion protein 1 (VCAM-1) induction in cultured human umbilical vein endothelial cells. We found that the drugs significantly suppressed VCam-1 induced by treatment with TNF-α in a dose-dependent manner. Our results suggest that T NF-α induces VCAM- 1 production via NF-ΚB, which can be blocked by the drugs.